TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.60
+0.54%Margins
Gross margin
84.0%
EBITDA margin
-2712.3%
EBIT margin
-2792.3%
Net margin
-2728.0%
FCF margin
-2471.7%
-38.6%
Return on equity
-31.8%
Return on assets
-34.6%
Return on invested capital
0.01x
Asset turnover
-$132.2M
Cash from operations
$1.40
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026